98. 好酸球性消化管疾患 Eosinophilic gastrointestinal disease Clinical trials / Disease details
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01498497 (ClinicalTrials.gov) | January 2012 | 16/12/2011 | A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021 | Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects] | Eosinophilic Esophagitis | Drug: EUR-1100;Drug: Placebo | Forest Laboratories | NULL | Completed | 12 Years | 55 Years | All | 14 | Phase 1/2 | United States |
2 | NCT01386112 (ClinicalTrials.gov) | September 2011 | 28/6/2011 | Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis | A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | Drug: EUR-1100;Drug: placebo | Aptalis Pharma | NULL | Completed | 12 Years | 55 Years | Both | 24 | Phase 1/Phase 2 | United States |